Market Research Report
Opioid Drugs: Global Markets to 2023
|Published by||BCC Research||Product code||750754|
|Published||Content info||147 Pages
Delivery time: 1-2 business days
|Opioid Drugs: Global Markets to 2023|
|Published: November 29, 2018||Content info: 147 Pages||
The global market for opioid drugs should reach $29.8 billion by 2023 from $26.4 billion in 2018 at a compound annual growth rate (CAGR) of 2.5% for the period of 2018-2023.
The buprenorphine drug segment of the global opioid drugs market is expected to grow from $5.1 billion in 2018 to $6.3 billion in 2023 at a CAGR of 4.4% for the period of 2018-2023.
The morphine drug segment of the global opioid drugs market is expected to grow from $5.0 billion in 2018 to $5.7 billion in 2023 at a CAGR of 2.7% for the period of 2018-2023.
The current report offers a detailed picture of the prescription opioid drug market. Prescription opioids are included in the scope of study; illegal opioids such as heroin, which are sold in illegal market for illicit usage, are not included. The market estimation includes all branded and generic opioid drugs indicated for different therapeutic application such as pain management and opioid use disorders.
This report highlights the current and future market potential of opioid drugs along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement and market dynamics.
The report details market shares of opioid drugs based on product and geography. Based on product, the market is segmented into buprenorphine, fentanyl, hydrocodone, morphine, oxycodone, tramadol and others. Each product segment includes detailed analyses covering an overview of drug, mechanism of action and market insights on each drug.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Germany, the U.K. France, Japan, China and India are covered in regional segments. For market estimates, data has been provided for the year 2017 and the base year of 2018 and forecast for 2023. Estimated values used are based on drug manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.